Disease-free survival (DFS) curves according to patient group. A, among 1,048 patients, ER-negative and PgR-negative and HER2-positive breast carcinoma tended to display the worst 5-year DFS, by log-rank analysis; ER-positive and/or PgR-positive and HER2-negative patients had the best 5-year overall survival; p < 0.0001. B, in the node-positive patients, TNBC tended to display a worse 5-year DFS by log-rank analysis; ER-positive and/or PgR-positive and HER2-negative patients had the best 5-year DFS; p = 0.0088. C, in the node-negative patients, four subgroups showed no 5-year DFS difference by log-rank analysis; p = 0.0720. We followed up the node-negative HER2-positive patients up to 48 months. ER, estrogen receptor; PgR, progesterone receptor; HER2, her2/neu gene over-expression.